Reviewer’s report

Title: Autoantibodies against angiotensin II type 1 receptor-positive patients with heart failure have better clinical efficacy of perindopril treatment

Version: 4 Date: 1 May 2013

Reviewer: Dusan Popadic

Reviewer’s report:

Major revisions

Title:

Autoantibodies against angiotensin II type 1 receptor-positive patients with heart failure have better clinical efficacy of perindopril treatment

If I understand correctly this should be: Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

Two duplicated sentences in methods (Anti-AT1-AR determination)
Authors should clarify what is blank and what is negative control (sample OD # blank OD/negative 10 control OD # blank OD) since this is an in-house EIA

... positive sera for AT1 receptor in CHF was 56.41 % (88/156), significantly higher than that in the control group. Authors should describe the aforementioned control group. I cannot see any data on this group in patients section or in table 1.

Authors should discuss more on the potential pathogenic/beneficial role of anti-angiotensin II type 1 receptor autoantibodies. What happens in the group of patients with autoantibodies disappearance or significant titer reduction (>4 fold) regarding primary outcome and LV remodeling? Also, some more discussion on the mechanisms of titer reduction or disappearance upon perindopril treatment would be appreciated.

English must be improved throughout the manuscript

Minor revisions:

Many typing and formatting errors throughout the manuscript
References should be uniform in terms of formatting (Journal abbreviations…)

Level of interest: An article of importance in its field

Quality of written English: Not suitable for publication unless extensively edited
**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

I declare that I have no competing interests